Diagnostic and management practices for phenylketonuria in 19 countries of the South and Eastern European Region: survey results

Abstract

To avoid potentially severe outcomes, phenylketonuria (PKU) must be detected as soon as possible after birth and managed with life-long treatment. A questionnaire-based survey was performed to document diagnosis and management practices for PKU in a region of Southern and Eastern Europe. Prevalence and management data were obtained from 37/59 (63 %) centres within 19/22 (86 %) contacted countries (N = 8600 patients). The main results’ analysis was based on completed questionnaires obtained from 31 centres (53 %) within 15 countries (68 %). A median of 10 % of patients per centre had been diagnosed after the newborn period. Metabolic dieticians and specialised adult PKU clinics were lacking in 36 and 84 % of centres, respectively. In 26 % of centres, treatment initiation was delayed until >15 days of life. Blood phenylalanine (Phe) thresholds to start treatment and upper Phe targets were inconsistent across centres. Ten percent of centres reported monitoring Phe every 2 weeks for pregnant women with PKU, which is insufficient to minimise risk of neonatal sequalae. Sapropterin dihydrochloride treatment was available in 48 % of centres, with 24-h responsiveness tests most common (36 %). Only one centre among the five countries lacking newborn screening provided a completed questionnaire.Conclusion: Targeted efforts by health care professionals and governments are needed to optimise diagnostic and management approaches for PKU in Southern and Eastern Europe.“What is Known”• PKU must be detected early and optimally managed throughout life to avoid poor outcomes, yet newborn screening is not universal and diagnostic and management practices for PKU are known to vary widely between different centres and countries. • Targeted efforts by health care professionals and governments are needed to optimise diagnostic and management approaches. “What is New”• PKU management practices are documented in 19 South and Eastern European countries indicating a heterogeneous situation across the region. • Key areas for improvement identified in surveyed centres include a need for comprehensive screening in all countries, increased number of metabolic dietitians and specialised adult PKU clinics, delayed time to treatment initiation, appropriate Phe thresholds, Phe targets and monitoring frequencies, and universal access to currently available treatment options. Electronic supplementary materialThe online version of this article (doi:10.1007/s00431-015-2622-5) contains supplementary material, which is available to authorized users.

Medical care of patients with disorders of aromatic amino acid metabolism: a report based on the Polish National Health Fund data records

“…It is an example of personalised medicine, which will most likely become medicine of the future. The role of newborn screening in reducing mortality in children and in providing specialist care for patients with inborn errors of metabolism has been emphasised by many authors [4,9,10]. Our analysis demon-strates that hospitalisations of patients after the second year of life were close to zero, which results from the specific characteristics of some of the disease entities whose treatment only rarely requires hospitalisation.…”

“…If left untreated, the disease damages the central nervous system, leading to intellectual disability and various neurological problems [1,2]. A rapid diagnosis and treatment are of key importance for the child's development [3][4][5].…”

Development of the US English version of the phenylketonuria – quality of life (PKU-QOL) questionnaire

“…Most of the cross-cultural evaluations currently published review diagnostic and management perspectives in various countries [32–35]. The availability of the PKU-QOL questionnaire in eight countries (i.e., France, Germany, Italy, The Netherlands, Spain, Turkey, UK and the US) will encourage cross-cultural research in PKU, and will be the first step to wider development and use in various cultural settings.…”

Microsomal Liver Function in Patients with Phenylketonuria Assessed by 13C-Methacetin Breath Test

“…The study group comprised of 20 subjects (13 females and 7 males) aged 15 -34 years with classical PKU from the department of pediatric gastroenterology and metabolic Inclusion criteria were defined as: the diagnosis of classical PKU based on the result of national newborn screening and confirmed by molecular tests (15,16), aged 15 years or older, and willingness to participate in the study. Exclusion criteria were: non-classical forms of PKU (mild PKU, maternal PKU, mild hyperphenylalaninemia, BH4 deficiency) and pregnancy.…”